logo

BIOA

BioAge Labs·NASDAQ
--
--(--)
--
--(--)
2.90 / 10
Underperform

Fundamental metrics for BIOA indicate a weak status (score 2.9/10). Key concerns include suboptimal Asset-MV and Revenue-MV ratios, while moderately positive factors such as Days sales outstanding and Interest coverage ratio offer limited support. The data suggest a defensive stance is warranted.

Fundamental(2.9)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.89
Score1/3
Weight8.81%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.87%
1M Return1.11%
Days sales outstanding
Value11.75
Score2/3
Weight1.91%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight17.50%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight17.52%
1M Return8.45%
PB-ROE
Value-0.36
Score3/3
Weight23.73%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.75%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.72%
1M Return0.43%
Asset-MV
Value-0.50
Score0/3
Weight12.50%
1M Return5.75%
Cash-MV
Value-0.07
Score2/3
Weight17.20%
1M Return8.41%
Is BIOA undervalued or overvalued?
  • BIOA scores 2.90/10 on fundamentals and holds a Premium valuation at present. Backed by its -18.20% ROE, 0.00% net margin, -10.95 P/E ratio, 3.12 P/B ratio, and 139.69% earnings growth, these metrics solidify its Underperform investment rating.